{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:46:34Z","timestamp":1771379194455,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This non\u2010interventional observational study described the current standard\u2010of\u2010care for transplant\u2010eligible newly diagnosed multiple myeloma (TE\u2010NDMM) patients in France, Germany, Spain, and Italy, and recorded the evolution in regimen adoption in distinct elements of frontline treatment during 2017\u20132020\/2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical information on ongoing (I) or previous (II) TE\u2010NDMM patients was extracted from the Cancerology database. Proportions of patients receiving regimens in each element and the evolution in regimen adoption were determined for the entire population and each country.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most common induction regimens among I patients were VRd in France (75.3%) and Spain (44.1%), VTd in Italy (65.2%), and regimens other than VRd\/VTd\/VCd in Germany. Maintenance was ongoing\/planned for 78.3%, 62.3%, 65.2%, and 61.4% patients in France, Germany, Spain, and Italy, respectively. Among II patients, VRd induction increased from 27.0% in 2017 to 65.7% in 2019 in France, remained relatively low in Spain and Germany, and not present in Italy. In Italy and Spain, VTd induction declined from 72.4% and 58.3% in 2017 to 52.8% and 17.3% in 2019, respectively. VCd induction in Germany declined from 85.2% in 2017 to 64.1% in 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of bortezomib triplets in induction varied markedly over time and between selected countries.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13821","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T08:38:26Z","timestamp":1656664706000},"page":"388-397","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real\u2010world study on adoption of standard\u2010of\u2010care for transplant\u2010eligible newly diagnosed multiple myeloma patients between 2017 and 2020\/2021 across France, Germany, Spain, and Italy"],"prefix":"10.1111","volume":"109","author":[{"given":"Katja","family":"Weisel","sequence":"first","affiliation":[{"name":"Department of Oncology, Hematology, BMT with Section of Pneumology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid Ottosson","family":"Wadlund","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag AB  Solna Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guntug","family":"Gungor","sequence":"additional","affiliation":[{"name":"Janssen, Kavac\u0131k  Beykoz\/\u0130stanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Dergarabetian","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Limited  Buckinghamshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Cerner Enviza France SAS  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-6050","authenticated-orcid":false,"given":"Nihar","family":"Masurkar","sequence":"additional","affiliation":[{"name":"Cerner Enviza France SAS  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Rodriguez\u2010Otero","sequence":"additional","affiliation":[{"name":"Department of Hematology Cl\u00ednica Universidad de Navarra  Pamplona Navarra Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.001"},{"key":"e_1_2_8_3_1","unstructured":"International Agency for Research on Cancer and World Health Organization.Multiple myeloma Source: Globocan 2020. Accessed February 16 2022.https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/35\u2010Multiple\u2010myeloma\u2010fact\u2010sheet.pdf"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S212526"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568915"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-693606"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4626"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2018-0004"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1143.1143"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15680"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2552"},{"key":"e_1_2_8_14_1","unstructured":"PerrotA AugustoV PierresM JavelotM GuilmetC ProdelM et al.Overview and evolution of treatment lines in multiple myeloma from 2014 to 2018: a retrospective study using the French national claim database (SNDS). European Hematology Association.2021."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14193"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568881"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.624661"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328324bc04"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-015-0826-3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.018"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000230"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000229"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332320"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13821","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T09:18:15Z","timestamp":1692436695000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/ejh.13821"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13821","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"2022-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}